Through a rigorous technique and interpretation of IHC, we have shown that these cases (group 3) represent less than 1% (5/585) of all MMR-D tumors, which validates IHC as the primary method to detect MMR deficiency in a broad spectrum of tumors. This evidence concerns the gene MRC1 and hyperinsulinemic hypoglycemia, familial, 4.